Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beigene Ltd ADR
(NQ:
BGNE
)
218.97
+6.58 (+3.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
July 07, 2023
From
BeiGene
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Fox and BeiGene and Encourages Investors to Contact the Firm
July 05, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
BeiGene Ltd. (NASDAQ: BGNE) is a Leading Gainer in Wednesday Morning Trading
July 05, 2023
Via
Investor Brand Network
What's Happening With Beigene Shares During Wednesday's Session
June 21, 2023
Beigene Ltd (NASDAQ: BGNE) shares are trading lower by 3.41% to $185.03 Wednesday morning on downward momentum following Tuesday weakness.
Via
Benzinga
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE
July 04, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
ROSEN, A LEADING LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE
July 03, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE
July 02, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
Bragar Eagel & Squire, P.C. Is Investigating EPAM, Castle, BeiGene and Fox and Encourages Investors to Contact the Firm
June 30, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023
June 30, 2023
Via
Benzinga
Why This BeiGene Analyst Slashes Forecast By Almost 42%
June 30, 2023
BeiGene Ltd (NASDAQ: BGNE) declined in early trading on Friday, maintaining its downward trajectory through the week amid weakness in Chinese stocks.
Via
Benzinga
NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday
June 30, 2023
Truist Securities boosted the price target for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $125 to $140. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. BioMarin Pharmaceutical...
Via
Benzinga
BEIGENE ALERT: Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. on Behalf of BeiGene Stockholders and Encourages Investors to Contact the Firm
June 26, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
BGNE INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE
June 17, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
Kirby McInerney LLP Continues Investigation of Shareholder Claims Against BeiGene, Ltd. (BGNE)
June 16, 2023
From
Kirby McInerney LLP
Via
Business Wire
BGNE LOSS ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE
June 16, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
June 16, 2023
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
June 15, 2023
From
The Schall Law Firm
Via
Business Wire
BGNE INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE
June 15, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent
June 15, 2023
BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics
Via
Benzinga
BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics
June 15, 2023
From
BeiGene
Via
Business Wire
Why MicroVision Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket
June 15, 2023
Gainers EdtechX Holdings Acquisition Corp. II (NASDAQ: EDTX) shares gained 139.8% to $26.54 in pre-market trading.
Via
Benzinga
Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 15, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
June 09, 2023
From
BeiGene
Via
Business Wire
BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
May 30, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
May 25, 2023
From
BeiGene
Via
Business Wire
Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting
May 25, 2023
Via
Benzinga
BeiGene to Present at Upcoming Investor Conferences
May 24, 2023
From
BeiGene
Via
Business Wire
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
May 22, 2023
Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor...
Via
Benzinga
The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
May 17, 2023
From
BeiGene
Via
Business Wire
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
May 06, 2023
From
BeiGene
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.